BSE:500672

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Novartis India Limited primarily trades in drugs and pharmaceuticals. More Details


Snowflake Analysis

Flawless balance sheet unattractive dividend payer.


Similar Companies

Share Price & News

How has Novartis India's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 500672 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.8%

500672

-0.8%

IN Pharmaceuticals

1.4%

IN Market


1 Year Return

-3.0%

500672

48.4%

IN Pharmaceuticals

2.8%

IN Market

Return vs Industry: 500672 underperformed the Indian Pharmaceuticals industry which returned 48.4% over the past year.

Return vs Market: 500672 underperformed the Indian Market which returned 2.8% over the past year.


Shareholder returns

500672IndustryMarket
7 Day-0.8%-0.8%1.4%
30 Day0.1%3.0%8.0%
90 Day3.2%12.3%7.8%
1 Year-1.4%-3.0%50.2%48.4%4.5%2.8%
3 Year5.1%0.2%25.7%22.3%-0.5%-5.3%
5 Year-21.0%-26.8%0.5%-3.1%41.5%31.0%

Price Volatility Vs. Market

How volatile is Novartis India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Novartis India undervalued compared to its fair value and its price relative to the market?

114.55x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500672 (₹634.8) is trading above our estimate of fair value (₹77.42)

Significantly Below Fair Value: 500672 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500672 is poor value based on its PE Ratio (114.5x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 500672 is poor value based on its PE Ratio (114.5x) compared to the Indian market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500672's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500672's PB Ratio (2.2x) is in line with the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Novartis India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novartis India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Novartis India performed over the past 5 years?

-27.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500672 has high quality earnings.

Growing Profit Margin: 500672's current net profit margins (3.2%) are lower than last year (9.2%).


Past Earnings Growth Analysis

Earnings Trend: 500672's earnings have declined by 27.5% per year over the past 5 years.

Accelerating Growth: 500672's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 500672 had negative earnings growth (-67.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 500672's Return on Equity (1.9%) is considered low.


Next Steps

Financial Health

How is Novartis India's financial position?


Financial Position Analysis

Short Term Liabilities: 500672's short term assets (₹8.1B) exceed its short term liabilities (₹2.3B).

Long Term Liabilities: 500672's short term assets (₹8.1B) exceed its long term liabilities (₹1.2B).


Debt to Equity History and Analysis

Debt Level: 500672 is debt free.

Reducing Debt: 500672 had no debt 5 years ago.

Debt Coverage: 500672 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500672 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Novartis India current dividend yield, its reliability and sustainability?

1.58%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500672's dividend (1.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.55%).

High Dividend: 500672's dividend (1.58%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).


Stability and Growth of Payments

Stable Dividend: 500672's dividends per share have been stable in the past 10 years.

Growing Dividend: 500672's dividend payments have not increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (180.4%), 500672's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Sanjay Murdeshwar (54 yo)

1.33yrs

Tenure

₹9,064,800

Compensation

Mr. Sanjay Prabhakar Murdeshwar serves as Vice Chairman and Managing Director at Novartis India Limited since June 15, 2019. Mr. Murdeshwar served as Managing Director of AstraZeneca Pharma India Limited s ...


CEO Compensation Analysis

Compensation vs Market: Sanjay's total compensation ($USD122.79K) is below average for companies of similar size in the Indian market ($USD316.55K).

Compensation vs Earnings: Insufficient data to compare Sanjay's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Murdeshwar
MD & Vice Chairman1.33yrs₹9.06mno data
Felix Doss
Chief Financial Officer1.33yrs₹15.00mno data
Trivikram Guda
Company Secretary & Compliance Officer3.67yrs₹8.40mno data
Vasant Narasimhan
Chief Executive Officer of Novartis2.67yrsno datano data

2.0yrs

Average Tenure

Experienced Management: 500672's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sanjay Murdeshwar
MD & Vice Chairman1.33yrs₹9.06mno data
Alex Krauer
Honorary Chairman of Novartis AGno datano datano data
Monaz Noble
Non-Executive Non-Independent Director4.33yrs₹13.90mno data
Jai Hiremath
Independent Director14.75yrs₹1.00mno data
Sanker Parameswaran
Independent Non-Executive Director0.33yrno datano data
Christopher Snook
Non-Executive Chairman12.17yrsno datano data
Sandra Martyres
Independent Non-Executive Director4.5yrs₹1.00mno data

4.4yrs

Average Tenure

63yo

Average Age

Experienced Board: 500672's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Novartis India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Novartis India Limited
  • Ticker: 500672
  • Exchange: BSE
  • Founded: 1947
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹15.674b
  • Shares outstanding: 24.69m
  • Website: https://www.novartis.in

Number of Employees


Location

  • Novartis India Limited
  • Inspire BKC, G Block
  • Part of 601 and 701
  • Mumbai
  • Maharashtra
  • 400051
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500672BSE (Mumbai Stock Exchange)YesEquity SharesININRApr 1999
NOVARTINDNSEI (National Stock Exchange of India)YesEquity SharesININRApr 1999

Biography

Novartis India Limited primarily trades in drugs and pharmaceuticals. The company offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences. It also pro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 12:32
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.